Shin Poong Pharm.Co.Ltd. (019170) fair value: what the stock is really worth
As of Nov 9, 2026: fair value (intrinsic value) of Shin Poong Pharm.Co.Ltd. stock KRW 3,597, price KRW 7,980, that is 54.9% below the price, quality 69 out of 100. Rating: strongly overvalued. Calculated from audited financials with 22 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.
How to read this chart
60‑month range 6,650 KRW – 95,304 KRW · fair‑value band 2,816 KRW – 4,425 KRW · the 7,980 KRW price screens above the 3,597 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.
Follow Shin Poong Pharm.Co.Ltd. in your weekly email
Every Wednesday you see whether Shin Poong Pharm.Co.Ltd. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Shinpoong Pharmaceutical Co.,Ltd, together with its subsidiaries, manufactures and sells pharmaceutical products in South Korea.
Show moreShow less
The company offers cephalosporin antibiotics; penicillin antibiotics; and finished products, as well as antivirals, anticancer drugs, painkillers, anti-inflammatory products, and anthelmintics.
It provides active pharmaceutical ingredients; Pyramax, an anti-malarial drug; and drugs for treating hypercholesterolemia, knee osteoarthritis and shoulder periarthritis, and surgical adhesion barrier; prescription drugs; wound dressings; health functional food; and over the counter products.
In addition, the company engages in business management and exports its products to approximately 50 countries. The company was founded in 1962 and is headquartered in Seoul, South Korea.
Stock analysis
Shin Poong Pharm.Co.Ltd. (019170) currently trades at 7,980 KRW, while our model-based Fair Value estimate is 3,597 KRW, 55% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of 4,148 KRW per share, and 1 of the 22 models we run sit above the 7,980 KRW price.
Bear case: the Earnings-Based group reads lowest at 2,285 KRW, and 21 of the 22 models stay below the price. Data coverage for this calculation is low.
Scenario range: 2,816 KRW (bear) to 4,425 KRW (bull), the price of 7,980 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 69/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Shin Poong Pharm.Co.Ltd. reported revenue of 235B KRW in FY2025 versus 189B KRW in FY2021, a compound +5.5%/yr. Reported net income was 8.8B KRW in FY2025.
Key figures
Market cap 429B KRW (≈ $317M) Small · P/S ratio 1.90 · EPS (TTM) −22.10 KRW · Net margin −0.3% · Return on equity −0.3% · Return on assets (EBIT) 0.7% (5-year average) · Operating margin −12.6% · Revenue (TTM) 239B KRW.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 23 out of 100 (medium confidence).
What moves the price
The share trades about 48% below its 52-week high and 11% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −55%, 019170 screens richer than that median.
Fair Value models
Bear2,816 KRWFair Value 3,597 KRWBull4,425 KRW
Price 7,980 KRW · Downside -54.9%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.62/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+6.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.5%
Start year 2020 (pandemic). Over 10 years: +1.8% a year
Revenue growth 22 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.9%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+11.0%
Earnings growth per share plus dividend.
Earnings per share, growth per year+11.0%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.4% → 6%
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+23.3%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about +20.8% a year for the price.
Compare Shin Poong Pharm.Co.Ltd. with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 549 stocks
Beats the industry median on 5/11 measures
A mixed picture versus its industry peers.
Valuation
Quality Score69 · Top 25%
Fair Value upside−54.6% · Bottom 25%
Profitability
Return on assets2.5% · Below median
Net margin (12 months)−0.3% · Bottom 25%
Operating margin (12 months)−12.6% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)9.0% · Above median
Balance sheet
Debt / equity0.04× · Below median
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/B1.58× · Cheaper than median
P/S (12 months)1.78× · Cheaper than median
Price / free cash flow (fiscal year)32.1× · Pricier than median
EV/EBITDA27.8× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 15
FUTURE (revenue growth)45· sector 25
PAST (return on equity)0· sector 29
HEALTH (low debt)98· sector 96
DIVIDEND (yield)0· sector 32
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Shin Poong Pharm.Co.Ltd. (019170) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of 3,597 KRW versus a price of 7,980 KRW, about 55% lower (overvalued).
What is the fair value of 019170?
Our model-based fair value for Shin Poong Pharm.Co.Ltd. is 3,597 KRW (as of Nov 8, 2026), built from audited fundamentals. The current price: 7,980 KRW.
What is the quality score of 019170?
Shin Poong Pharm.Co.Ltd. has a Quality Score of 69/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Shin Poong Pharm.Co.Ltd. (019170)?
Our model-based price target is the fair value of 3,597 KRW (as of Nov 8, 2026) from 22 valuation models. Cautious scenario 2,816 KRW, optimistic scenario 4,425 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Shin Poong Pharm.Co.Ltd. stock forecast for 2026?
Our models put fair value at 3,597 KRW, about 55% lower versus a price of 7,980 KRW (overvalued). Cautious scenario 2,816 KRW, optimistic scenario 4,425 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Shin Poong Pharm.Co.Ltd. (019170)?
Shin Poong Pharm.Co.Ltd. reported trailing-twelve-month revenue of about 239B KRW (latest available figure, as of Nov 8, 2026).
What growth is priced into Shin Poong Pharm.Co.Ltd. (019170)?
For today's price to be fair in a discounted-cash-flow model, Shin Poong Pharm.Co.Ltd. would have to grow free cash flow by +23.3 % per year for five years (discount rate 12.0 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +3.5 % per year. As of Nov 8, 2026.
What discount rate (WACC) does the fair value of 019170 use?
Our models discount Shin Poong Pharm.Co.Ltd. at 12.0 %: a base by market capitalisation (small), damped by beta 1.14, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Shin Poong Pharm.Co.Ltd. that is +23.3 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (12.0 %) and the same formula as our fair value.
How much growth has Shin Poong Pharm.Co.Ltd. (019170) delivered so far?
Over the past 5 years revenue at Shin Poong Pharm.Co.Ltd. grew +3.5 % a year. The price currently implies free-cash-flow growth of +23.3 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Shin Poong Pharm.Co.Ltd. (019170) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Shin Poong Pharm.Co.Ltd. (+23.3 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Shin Poong Pharm.Co.Ltd. (019170)?
The free-cash-flow yield on the price is 3.37 %: that much free cash flow Shin Poong Pharm.Co.Ltd. produces per unit of market value. When it exceeds the discount rate of our models (12.0 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Shin Poong Pharm.Co.Ltd. (019170)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Shin Poong Pharm.Co.Ltd. it is 3,597 KRW per share (as of Nov 8, 2026), against a price of 7,980 KRW. It is the blended result of 22 valuation models in 7 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Shin Poong Pharm.Co.Ltd. stock overvalued or undervalued in 2026?
As of Nov 8, 2026, 019170 trades above its calculated fair value: price 7,980 KRW, fair value 3,597 KRW, a gap of about −55% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 019170?
No. The price is what the market pays today (7,980 KRW); the fair value is what the company's own numbers justify (3,597 KRW). For Shin Poong Pharm.Co.Ltd. the two are 4,383 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Shin Poong Pharm.Co.Ltd. worth?
The market values Shin Poong Pharm.Co.Ltd. at about 429B KRW (market capitalisation, as of Nov 8, 2026). Per share that is 7,980 KRW; our models calculate a fair value of 3,597 KRW per share.
What do the bullish and bearish scenarios say about 019170?
Our models span a range for Shin Poong Pharm.Co.Ltd.: cautious scenario 2,816 KRW, base 3,597 KRW, optimistic 4,425 KRW per share (as of Nov 8, 2026, price 7,980 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Shin Poong Pharm.Co.Ltd. (019170)?
Balance-sheet figures for Shin Poong Pharm.Co.Ltd. (as of Nov 8, 2026): return on equity −0.3%, debt of 0.04 per unit of equity. They feed the Quality Score of 69/100, which measures business quality independently of the share price.
How far is 019170 from its 52-week high?
Shin Poong Pharm.Co.Ltd. trades at 7,980 KRW, about 48% below its 52-week high of 15,340 KRW and 11% above the low of 7,210 KRW (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of 3,597 KRW is for.
Which stocks are comparable to Shin Poong Pharm.Co.Ltd.?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Shin Poong Pharm.Co.Ltd. stock attractive at the current price?
The data as of Nov 8, 2026: price 7,980 KRW, calculated fair value 3,597 KRW (−55%), Quality Score 69/100, from 22 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 019170 calculated?
We run Shin Poong Pharm.Co.Ltd. through 22 models from 7 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 3,597 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Shin Poong Pharm.Co.Ltd. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Shin Poong Pharm.Co.Ltd. (019170)?
The closing price on Nov 9, 2026 was 7,980 KRW. Our model-based fair value is 3,597 KRW, about 55% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Shin Poong Pharm.Co.Ltd. right now?
The price sits above even our optimistic bull case (4,425 KRW). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (69/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Shin Poong Pharm.Co.Ltd.
How large is the market capitalisation of Shin Poong Pharm.Co.Ltd. (019170)?
The market capitalisation of Shin Poong Pharm.Co.Ltd. is 429B KRW (≈ $317M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Shin Poong Pharm.Co.Ltd. (019170)?
The price-to-sales ratio of Shin Poong Pharm.Co.Ltd. is 1.90 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Shin Poong Pharm.Co.Ltd. (019170)?
Earnings per share at Shin Poong Pharm.Co.Ltd. are −22.10 KRW. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Shin Poong Pharm.Co.Ltd. (019170)?
The net margin of Shin Poong Pharm.Co.Ltd. is −0.3% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Shin Poong Pharm.Co.Ltd. (019170)?
The return on equity (ROE) of Shin Poong Pharm.Co.Ltd. is −0.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Shin Poong Pharm.Co.Ltd. (019170)?
On an EBIT basis the return on assets of Shin Poong Pharm.Co.Ltd. is 0.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Shin Poong Pharm.Co.Ltd. (019170)?
The operating margin of Shin Poong Pharm.Co.Ltd. is −12.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Shin Poong Pharm.Co.Ltd. (019170)?
Revenue at Shin Poong Pharm.Co.Ltd. is growing +9.0% versus a year earlier (3y avg +3.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Shin Poong Pharm.Co.Ltd. (019170)?
Earnings per share at Shin Poong Pharm.Co.Ltd. are growing −81.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Shin Poong Pharm.Co.Ltd. (019170) carry?
The net debt of Shin Poong Pharm.Co.Ltd. is 7.5B KRW (fiscal year 2025, ≈ 0.6 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Shin Poong Pharm.Co.Ltd. in the live analysis
One click puts Shin Poong Pharm.Co.Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 8, 2026